Digital Therapeutics vs Wellness Apps: Key Differences
The claim you make decides your category — not your product's design, and not how clinical it feels to use. A digital therapeutic (DTx) claims to treat, manage, or prevent a specific medical condition, and in the US that claim generally needs FDA clearance before you're allowed to make it in public. A wellness app makes no treatment claim, so it stays outside that regulatory perimeter — and outside the reimbursement lane that comes with it. Everything downstream, from your evidence bar to your fundraising timeline, follows from that one decision.
Quick answer: Digital therapeutics are software products that assert a treatment claim, backed by clinical evidence and, in the US, FDA regulatory clearance. Wellness apps make no treatment claim, so they skip that regulatory burden — and skip the payer reimbursement it unlocks. Which one you're building isn't a marketing choice; it's a determination your legal and regulatory counsel has to make, not one you make yourself.
Digital Therapeutics vs. Wellness Apps: Side-by-Side
The two paths diverge on five dimensions that compound on each other: how much evidence you need before launch, which regulator reviews you (if any), who pays for access, how you reach users, and how long the whole process takes.
| Dimension | Wellness App | Digital Therapeutic (DTx) |
|---|---|---|
| Evidence bar | Founder discretion — engagement metrics and user testimonials are typically sufficient | Clinical evidence from controlled studies, sized to the strength of the claim being made |
| Regulation (US) | Generally outside FDA's medical device framework, provided no treatment claim is made | Reviewed as Software as a Medical Device (SaMD), commonly via the FDA's 510(k) or De Novo pathway |
| Payer / reimbursement | Consumer-paid: subscription, freemium, or B2B2C through an employer wellness budget | Prescribed or reimbursed like a medical treatment, once payer contracts and billing codes are negotiated |
| Distribution | App stores, direct-to-consumer marketing, employer wellness benefits | Clinician prescription, health system formularies, payer-negotiated access |
| Time to market | Months — ship, measure, iterate | Years — clinical trial design, a formal regulatory submission, and review, before the claim can be made publicly |
Read the table as a single trade-off, not five independent choices: everything a digital therapeutic gains in payer access and clinical credibility, it pays for in time, capital, and a regulatory dependency a wellness app never takes on.
When the Wellness App Path Wins
Choose the wellness path when speed to market and consumer reach matter more than a formal treatment claim or payer reimbursement — which describes most mental health apps, most of the time.
The wellness path fits when:
- Your business model is consumer-paid, not payer-reimbursed. Subscriptions, freemium upgrades, and employer wellness budgets don't require a treatment claim or FDA clearance to access.
- You're still validating the core problem. Before you've proven people actually want the product, spending years and meaningful capital on a regulatory submission is premature — validate a mental health app idea with real user signal first, the same way you'd validate any product, before committing to a heavier path.
- Your product is supportive or educational, not diagnostic. Journaling, mood tracking, guided meditation, psychoeducation, and habit-building tools generally don't need to claim they treat a condition to deliver real value.
- Speed is the strategy. A wellness app can ship, test a positioning claim, and iterate in weeks. A DTx submission is measured in years before you're allowed to make the equivalent claim publicly.
The trade-off is real: no treatment claim means no payer reimbursement, and no formal clinical validation means a harder time earning trust with clinicians who might otherwise refer users to you.
A mental health app is not a crisis tool — full stop. If your product touches mental health in any way, it needs a clear, always-visible pathway to real emergency help: in the US, the 988 Suicide & Crisis Lifeline, or 911 for immediate danger. This isn't a legal checkbox to bury in a settings menu — no consumer app, wellness or DTx alike, is equipped to manage acute suicidal ideation or self-harm risk inside the product itself. Design for the handoff to real help, not for containing the moment in your UI.
When Digital Therapeutics Make Sense
Choose the DTx path when the clinical outcome itself is the product you're selling — and you have the capital and timeline to prove it before you can say so.
Signals the DTx path fits your idea:
- The condition has an established diagnostic and treatment framework. Substance use disorder, insomnia, ADHD, and post-traumatic stress are the areas that have seen the most FDA activity, because there's an existing clinical protocol to translate into software.
- Your go-to-market depends on clinician prescription or payer contracts, not app-store discovery. If clinicians won't refer patients to you without a real evidence base, you need to build one.
- You can fund a multi-year runway that covers clinical trial design, a regulatory submission, and the wait for review — before a single reimbursed dollar arrives.
- You have, or can hire, real regulatory expertise. FDA's Digital Health Center of Excellence reviews software as a medical device under pathways like 510(k) or De Novo depending on whether a predicate device exists, and getting the pathway wrong costs you a resubmission cycle, not just a fee.
The category has real casualties worth knowing before you commit capital to it. Pear Therapeutics was the first company to win FDA clearance for a prescription digital therapeutic — reSET, for substance use disorder — and went on to go public, only to file for bankruptcy in 2023. Clinical clearance solved the regulatory problem; it didn't solve the reimbursement one. On the other side, Akili Interactive's EndeavorRx, a video-game-based digital therapeutic for pediatric ADHD, cleared FDA review through the De Novo pathway in 2020 and shows the category can work when the clinical claim, the evidence, and the payer strategy are aligned from the start.
None of this tells you which bucket your specific product falls into. Whether your product is SaMD, which pathway applies, and what evidence a submission needs are regulatory and legal questions, not product ones. Get counsel with FDA digital health experience before you commit to a treatment claim, or to a go-to-market plan that assumes one.
The Middle Ground: Clinically Informed Wellness Products
Most mental health startups end up here, whether they planned to or not: wellness products built on evidence-based clinical frameworks — cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), acceptance and commitment therapy (ACT) — without making a formal treatment claim or pursuing FDA clearance.
A clinically informed wellness product uses a real, well-established therapeutic framework as the design foundation for its content and exercises, while stopping short of asserting that the app itself treats a diagnosed condition. The distinction lives almost entirely in your language: "grounded in CBT principles" is a design credential; "treats your anxiety" is a regulatory claim. Getting that line wrong in your marketing copy, even with a well-intentioned product, is how a wellness app accidentally becomes an unregulated medical claim.
This middle ground works because it captures most of the credibility benefit of an evidence-based product without the multi-year cost of a formal treatment claim. It also demands more rigor than a generic wellness app, not less: if you're going to say your content is grounded in CBT, you should be able to show — to users, to clinical advisors, to investors — exactly which framework, which techniques, and ideally some review by a licensed clinician. Founders often skip this step; the clinical evidence bar for digital health startups covers what "clinically informed" should actually mean in practice, and how thin most claims to it really are once you look closely.
Regardless of where your product sits on this spectrum, the crisis-resource requirement above doesn't move. A clinically informed design vocabulary doesn't change the underlying fact: no consumer app — wellness, clinically informed, or a cleared digital therapeutic — is a substitute for emergency care when someone is in crisis. Whichever category you're building toward, the underlying discipline is the same one that applies to any startup bet: validate before you build. If you haven't worked through it yet, startup idea validation fundamentals apply here just as much as they would to any other product, before you commit six or seven figures to a wellness build or a DTx regulatory strategy.
Key Takeaways
- The claim decides the category, not the product. Software that claims to treat, manage, or prevent a specific condition needs to clear FDA review before making that claim in the US; software that makes no such claim doesn't.
- Wellness wins on speed, DTx wins on payer access. A wellness app can ship in months on consumer revenue; a digital therapeutic takes years but unlocks clinician prescription and payer reimbursement.
- The middle ground is real and common. Building on evidence-based frameworks like CBT, DBT, or ACT without a formal treatment claim captures credibility without the multi-year regulatory cost — as long as your marketing language matches your actual evidence.
- Regulatory clearance doesn't guarantee commercial viability. Pear Therapeutics held the first FDA-cleared prescription digital therapeutic and still filed for bankruptcy in 2023 — clinical clearance and reimbursement are two separate problems.
- Crisis pathways are non-negotiable. Any mental health product, regardless of category, needs a visible route to 988 or 911 — no app substitutes for emergency care in a crisis.
- This is a legal determination, not a marketing one. Whether your specific product qualifies as a digital therapeutic under FDA's framework needs regulatory counsel, not a founder's best guess.
Frequently Asked Questions
What is the difference between a digital therapeutic and a wellness app?
A digital therapeutic makes a claim to treat, manage, or prevent a specific medical condition and is backed by clinical evidence and, in the US, FDA regulatory clearance. A wellness app makes no treatment claim, so it isn't reviewed under that framework and can't access payer reimbursement built for medical treatment.
Does a mental health app need FDA clearance to launch?
Only if it makes a treatment claim for a specific condition. Educational, supportive, or mood-tracking tools that don't claim to treat a diagnosis generally launch without FDA review — but whether your specific product crosses that line is a determination for regulatory counsel, not a founder's judgment call.
Can a wellness app say it helps with anxiety or depression?
It can describe supportive features — journaling, guided breathing, psychoeducation — without asserting it treats the condition. The line between "may help you manage stress" and "treats anxiety" is exactly the line separating a wellness app from a regulated digital therapeutic, and it's worth getting legal review on your actual marketing copy, not just your product design.
Which path is faster to bring to market, wellness or digital therapeutics?
Wellness, by a wide margin. A wellness app can ship, test, and iterate in a matter of months on a consumer go-to-market. A digital therapeutic requires clinical evidence generation and a formal FDA submission before you're allowed to make a treatment claim publicly — typically a multi-year process.